UNIVERSITAS
GADJAH MADA
ANALISIS FARMAKOEKONOMI AROMATASE INHIBITOR GENERASI KETIGA PADA TERAPI KANKER PAYUDARA ER+ HER2- PASCAMENOPAUSE
RIA ETIKASARI, Prof. Dr. apt. Tri Murti Andayani, Sp.FRS
Universitas Gadjah Mada, 2022 | Diunduh dari http://etd.repository.ugm.ac.id/

DAFTAR PUSTAKA

Abubakar, M.B., Wei, K., dan Gan, S.H., 2014. The influence of genetic polymorphisms on the efficacy and side effects of anastrozole in postmenopausal breast cancer patients. *Pharmacogenetics and Genomics*, **24**: 575.

Aisyah, N., Andayani, T.M., dan Puspandari, D.A., 2018. Analisis Biaya Kemoterapi pada Pasien Rawat Inap Kanker Payudara Peserta JKN di RSUD Ulin Banjarmasin. *Jurnal Ilmiah Ibnu Sina*, **3**: 333–342.

Aisyah, N. dan Dina, S., 2020. COST OF ILLNESS PADA PASIEN PENYAKIT KANKER PAYUDARA DI RSUD ULIN BANJARMASIN. *Jurnal Ilmiah Ibnu Sina*, **5**: 407–415.

Andayani, T.M., 2013. *Farmakoekonomi : Prinsip Dan Metodologi*. Bursa Ilmu, Yogyakarta.

Anderson, W.F., Rosenberg, P.S., Prat, A., Perou, C.M., dan Sherman, M.E., 2014. How many etiological subtypes of breast cancer: two, three, four, or more? *Journal of the National Cancer Institute*, **106**: .

Anonim, 2003. ASHP guidelines on documenting pharmaceutical care in patient medical records. *American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists*, **60**: 705–707.

Anonim, 2018. *Pedoman Persiapan Pengadaan Bangunan Dan Pusat Pelayanan Radioterapu*. Perhimpunan Dokter Spesialis Onkologi Radiasi Indonesia.

Asten, K.V., Neven, P., Lintermans, A., Wildiers, H., dan Paridaens, R., 2014. Aromatase inhibitors in the breast cancer clinic: focus on exemestane. *Endocrine-Related Cancer*, **21**: R31–R49.

Aydiner, A., 2013. Meta-analysis of breast cancer outcome and toxicity in adjuvant trials of aromatase inhibitors in postmenopausal women. *Breast (Edinburgh, Scotland)*, **22**: 121–129.

Bahrami, N., Jabeen, S., Tahiri, A., Sauer, T., Ødegård, H.P., Geisler, S.B., dkk., 2021. Lack of cross-resistance between non-steroidal and steroidal aromatase inhibitors in breast cancer patients: the potential role of the adipokine leptin. *Breast cancer research and treatment*, **190**: 435–449.

Barnadas, A., Estévez, L.G., Lluch-Hernández, A., Rodriguez-Lescure, Á., Rodriguez-Sanchez, C., dan Sanchez-Rovira, P., 2011. An Overview of Letrozole in Postmenopausal Women with Hormone-Responsive Breast Cancer. *Advances in Therapy*, **28**: 1045–1058.

UNIVERSITAS GADJAH MADA
ANALISIS FARMAKOEKONOMI AROMATASE INHIBITOR GENERASI KETIGA PADA TERAPI KANKER PAYUDARA ER+ HER2- PASCAMENOPAUSE
RIA ETIKASARI, Prof. Dr. apt. Tri Murti Andayani, Sp.FRS
Universitas Gadjah Mada, 2022 | Diunduh dari http://etd.repository.ugm.ac.id/

Beck, J.T., Hortobagyi, G.N., Campone, M., Lebrun, F., Deleu, I., Rugo, H.S., dkk., 2014. Everolimus plus exemestane as first-line therapy in HR^+, $HER2^-$ advanced breast cancer in BOLERO-2. *Breast cancer research and treatment*, **143**: 459–467.

Bhatnagar, A.S., Häusler, A., dan Schieweck, K., 1990a. Inhibition of aromatase in vitro and in vivo by aromatase inhibitors. *Journal of enzyme inhibition*, **4**: 179–186.

Bhatnagar, A.S., Häusler, A., Schieweck, K., Lang, M., dan Bowman, R., 1990b. Highly selective inhibition of estrogen biosynthesis by CGS 20267, a new non-steroidal aromatase inhibitor. *The Journal of steroid biochemistry and molecular biology*, **37**: 1021–1027.

Bighin, C., Dozin, B., Poggio, F., Ceppi, M., Bruzzi, P., D'Alonzo, A., dkk., 2017. Hormonal therapy followed by chemotherapy or the reverse sequence as first-line treatment of hormone-responsive, human epidermal growth factor receptor-2 negative metastatic breast cancer patients: results of an observational study. *Oncotarget*, **8**: 44800–44810.

Bodrogi József dan Kaló Zoltán, 2010. Principles of pharmacoeconomics and their impact on strategic imperatives of pharmaceutical research and development. *British Journal of Pharmacology*, **159**: 1367–1373.

Brown, M. dan Farquhar-Smith, P., 2017. Pain in cancer survivors; filling in the gaps. *British journal of anaesthesia*, **119**: 723–736.

Buzdar, A.U., Robertson, J.F.R., Eiermann, W., dan Nabholtz, J.-M., 2002. An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane. *Cancer*, **95**: 2006–2016.

Campos, S.M., Guastalla, J.P., Subar, M., Abreu, P., Winer, E.P., dan Cameron, D.A., 2009. A comparative study of exemestane versus anastrozole in patients with postmenopausal breast cancer with visceral metastases. *Clinical breast cancer*, **9**: 39–44.

Chumsri, S., Howes, T., Bao, T., Sabnis, G., dan Brodie, A., 2011. Aromatase, aromatase inhibitors, and breast cancer. *The Journal of Steroid Biochemistry and Molecular Biology*, , Targeted Inhibitors for Steroid Transforming Enzymes **125**: 13–22.

Coates, A.S., Keshaviah, A., Thürlimann, B., Mouridsen, H., Mauriac, L., Forbes, J.F., dkk., 2007. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*, **25**: 486–492.

UNIVERSITAS
GADJAH MADA
ANALISIS FARMAKOEKONOMI AROMATASE INHIBITOR GENERASI KETIGA PADA TERAPI KANKER PAYUDARA ER+ HER2- PASCAMENOPAUSE
RIA ETIKASARI, Prof. Dr. apt. Tri Murti Andayani, Sp.FRS
Universitas Gadjah Mada, 2022 | Diunduh dari http://etd.repository.ugm.ac.id/

Coombes, R.C., Hall, E., Gibson, L.J., Paridaens, R., Jassem, J., Delozier, T., dkk., 2004. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. *The New England journal of medicine*, **350**: 1081–1092.

Costa, W.A., Eleutério, J., Jr, Giraldo, P.C., dan Gonçalves, A.K., 2017a. Quality of life in breast cancer survivors. *Revista da Associacao Medica Brasileira (1992)*, **63**: 583–589.

Costa, W.A., Monteiro, M.N., Queiroz, J.F., dan Gonçalves, A.K., 2017b. Pain and quality of life in breast cancer patients. *Clinics (Sao Paulo, Brazil)*, **72**: 758–763.

Coudert, B., Asselain, B., Campone, M., Spielmann, M., Machiels, J.-P., Pénault-Llorca, F., dkk., 2012. Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node-positive breast cancer: the 8-year follow-up results of the UNICANCER-PACS01 trial. *The oncologist*, **17**: 900–909.

Courtney, M. dan Chang, K., 2018. Dealing with non-normality: an introduction and step-by-step guide using R: Dealing with non-normality. *Teaching Statistics*, **40**: .

De Mil, R., Guillaume, E., Launay, L., Guittet, L., Dejardin, O., Bouvier, V., dkk., 2019. Cost-Effectiveness Analysis of a Mobile Mammography Unit for Breast Cancer Screening to Reduce Geographic and Social Health Inequalities. *Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research*, **22**: 1111–1118.

De Vos, F.Y.F.L., van Laarhoven, H.W.M., Laven, J.S.E., Themmen, A.P.N., Beex, L.V.A.M., Sweep, C.G.J., dkk., 2012. Menopausal status and adjuvant hormonal therapy for breast cancer patients: a practical guideline. *Critical reviews in oncology/hematology*, **84**: 252–260.

Dombernowsky, P., Smith, I., Falkson, G., Leonard, R., Panasci, L., Bellmunt, J., dkk., 1998. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*, **16**: 453–461.

Dranitsaris, G., Verma, S., dan Trudeau, M., 2003. Cost Utility Analysis of First-Line Hormonal Therapy in Advanced Breast Cancer: Comparison of Two Aromatase Inhibitors to Tamoxifen. *American Journal of Clinical Oncology*, **26**: 289.

UNIVERSITAS
GADJAH MADA
ANALISIS FARMAKOEKONOMI AROMATASE INHIBITOR GENERASI KETIGA PADA TERAPI KANKER PAYUDARA ER+ HER2- PASCAMENOPAUSE
RIA ETIKASARI, Prof. Dr. apt. Tri Murti Andayani, Sp.FRS
Universitas Gadjah Mada, 2022 | Diunduh dari http://etd.repository.ugm.ac.id/

Edejer, T. Tan-Torres, Baltussen, R, Adam, T, Hutubessy, R, Acharya, A, Evans, D. B, dkk. (Eds.), 2003. *WHO Guide to Cost-Effectiveness Analysis*. Genewa, World Health Organization.

Efthymiadou, O., Mossman, J., dan Kanavos, P., 2018. DIFFERENTIATION OF HEALTH-RELATED QUALITY OF LIFE OUTCOMES BETWEEN FIVE DISEASE AREAS: RESULTS FROM AN INTERNATIONAL SURVEY OF PATIENTS. *International journal of technology assessment in health care*, **34**: 498–506.

Endarti, D., Riewpaiboon, A., Thavorncharoensap, M., Praditsitthikorn, N., Hutubessy, R., dan Kristina, S.A., 2015. Evaluation of Health-Related Quality of Life among Patients with Cervical Cancer in Indonesia. *Asian Pacific journal of cancer prevention : APJCP*, **16**: 3345–3350.

Evans, T.R., Di Salle, E., Ornati, G., Lassus, M., Benedetti, M.S., Pianezzola, E., dkk., 1992. Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women. *Cancer research*, **52**: 5933–5939.

Finn, R.S., Martin, M., Rugo, H.S., Jones, S., Im, S.-A., Gelmon, K., dkk., 2016a. Palbociclib and Letrozole in Advanced Breast Cancer. *The New England journal of medicine*, **375**: 1925–1936.

Fleming, T.R., Rothmann, M.D., dan Lu, H.L., 2009. Issues in Using Progression-Free Survival When Evaluating Oncology Products. *Journal of Clinical Oncology*, **27**: 2874–2880.

Freites-Martinez, A., Santana, N., Arias-Santiago, S., dan Viera, A., 2021. Using the Common Terminology Criteria for Adverse Events (CTCAE - Version 5.0) to Evaluate the Severity of Adverse Events of Anticancer Therapies. *Actas dermo-sifiliograficas*, **112**: 90–92.

Geisler, J., 2011. Differences between the non-steroidal aromatase inhibitors anastrozole and letrozole – of clinical importance? *British Journal of Cancer*, **104**: 1059–1066.

Genuino, A.J., Chaikledkaew, U., Guerrero, A.M., Reungwetwattana, T., dan Thakkinstian, A., 2019. Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines. *BMC health services research*, **19**: 874.

Glare, P.A., Davies, P.S., Finlay, E., Gulati, A., Lemanne, D., Moryl, N., dkk., 2014. Pain in cancer survivors. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*, **32**: 1739–1747.

Goss, P.E., Ingle, J.N., Pritchard, K.I., Ellis, M.J., Sledge, G.W., Budd, G.T., dkk., 2013. Exemestane versus anastrozole in postmenopausal women with early breast

UNIVERSITAS GADJAH MADA
ANALISIS FARMAKOEKONOMI AROMATASE INHIBITOR GENERASI KETIGA PADA TERAPI KANKER PAYUDARA ER+ HER2- PASCAMENOPAUSE
RIA ETIKASARI, Prof. Dr. apt. Tri Murti Andayani, Sp.FRS
Universitas Gadjah Mada, 2022 | Diunduh dari http://etd.repository.ugm.ac.id/

cancer: NCIC CTG MA.27--a randomized controlled phase III trial. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*, **31**: 1398–1404.

Greenlee, H., Balneaves, L.G., Carlson, L.E., Cohen, M., Deng, G., Hershman, D., dkk., 2014. Clinical practice guidelines on the use of integrative therapies as supportive care in patients treated for breast cancer. *Journal of the National Cancer Institute. Monographs*, **2014**: 346–358.

Hasegawa, Y., Tanino, H., Horiguchi, J., Miura, D., Ishikawa, T., Hayashi, M., dkk., 2015. Randomized Controlled Trial of Zoledronic Acid plus Chemotherapy versus Chemotherapy Alone as Neoadjuvant Treatment of HER2-Negative Primary Breast Cancer (JONIE Study). *PloS one*, **10**: e0143643.

Hashemi-Meshkini, A., Keshavarz, K., Gharibnaseri, Z., Kheirandish, M., Kebriaeezadeh, A., Nikfar, S., dkk., 2013. Cost-effectiveness analysis review of exemestane in the treatment of primary and advanced breast cancer. *Archives of Medical Science : AMS*, **9**: 472–478.

Hatteville, L., Mahe, C., dan Hill, C., 2002. Prediction of the long-term survival in breast cancer patients according to the present oncological status. *Statistics in medicine*, **21**: 2345–2354.

Héquet, D., Huchon, C., Soilly, A.-L., Asselain, B., Berseneff, H., Trichot, C., dkk., 2019. Direct medical and non-medical costs of a one-year care pathway for early operable breast cancer: Results of a French multicenter prospective study. *PloS one*, **14**: e0210917.

Hong, Y. dan Chen, S., 2006. Aromatase Inhibitors. *Annals of the New York Academy of Sciences*, **1089**: 237–251.

Huang, S.-Y., Chen, H.-M., Liao, K.-H., Ko, B.-S., dan Hsiao, F.-Y., 2020. Economic burden of cancers in Taiwan: a direct and indirect cost estimate for 2007-2017. *BMJ open*, **10**: e036341.

Huang, W., Yang, J., Liu, Y., Liu, C., Zhang, X., Fu, W., dkk., 2018. Assessing health-related quality of life of patients with colorectal cancer using EQ-5D-5L: a cross-sectional study in Heilongjiang of China. *BMJ open*, **8**: e022711–e022711.

Huber, J.C., Ott, J., dan Tempfer, C.B., 2007. Preventive oncology in the postmenopausal woman. *Women's health (London, England)*, **3**: 689–697.

Ingle, J.N., 2013. Postmenopausal women with hormone receptor-positive breast cancer: balancing benefit and toxicity from aromatase inhibitors. *Breast (Edinburgh, Scotland)*, **22 Suppl 2**: S180-183.

Iqlima, Endarti, D., Wiedyaningsih, C., dan Haris, R.N.H., 2019. Measurement of Health Related Quality of Lifein General Population in Indonesia usingEQ-5D-5L

UNIVERSITAS GADJAH MADA
ANALISIS FARMAKOEKONOMI AROMATASE INHIBITOR GENERASI KETIGA PADA TERAPI KANKER PAYUDARA ER+ HER2- PASCAMENOPAUSE
RIA ETIKASARI, Prof. Dr. apt. Tri Murti Andayani, Sp.FRS
Universitas Gadjah Mada, 2022 | Diunduh dari http://etd.repository.ugm.ac.id/

with Online Survey. *International Journal of Pharma Sciences and Research*, **10**: 175–181.

Iragorri, N., de Oliveira, C., Fitzgerald, N., dan Essue, B., 2021. The Indirect Cost Burden of Cancer Care in Canada: A Systematic Literature Review. *Applied health economics and health policy*, **19**: 325–341.

Irwan, I., Azamris, A., dan Bachtiar, H., 2016. Perbandingan Prognosis Subtipe Molekuler Kanker Payudara Antara Pasien Kanker Payudara Wanita Usia Muda dan Tua di RSUP DR. M. DJAMIL PADANG. *Majalah Kedokteran Andalas*, **38**: 208–217.

Iveson, T.J., Smith, I.E., Ahern, J., Smithers, D.A., Trunet, P.F., dan Dowsett, M., 1993a. Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in healthy postmenopausal women. *The Journal of clinical endocrinology and metabolism*, **77**: 324–331.

Iwata, H., Masuda, N., Ohno, S., Rai, Y., Sato, Y., Ohsumi, S., dkk., 2013. A randomized, double-blind, controlled study of exemestane versus anastrozole for the first-line treatment of postmenopausal Japanese women with hormone-receptor-positive advanced breast cancer. *Breast cancer research and treatment*, **139**: 441–451.

Jo, C., 2014. Cost-of-illness studies: concepts, scopes, and methods. *Clinical and Molecular Hepatology*, **20**: 327–337.

Johannessen, D.C., Engan, T., Di Salle, E., Zurlo, M.G., Paolini, J., Ornati, G., dkk., 1997. Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study. *Clinical cancer research : an official journal of the American Association for Cancer Research*, **3**: 1101–1108.

Jonat, W., Howell, A., Blomqvist, C., Eiermann, W., Winblad, G., Tyrrell, C., dkk., 1996. A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. *European journal of cancer (Oxford, England : 1990)*, **32A**: 404–412.

Kaklamani, V.G., 2016. Clinical Implications of the Progression-Free Survival Endpoint for Treatment of Hormone Receptor-Positive Advanced Breast Cancer. *The Oncologist*, **21**: 922–930.

Kaufmann, M., Bajetta, E., Dirix, L.Y., Fein, L.E., Jones, S.E., Zilembo, N., dkk., 2000. Exemestane improves survival in metastatic breast cancer: results of a phase III randomized study. *Clinical breast cancer*, **1 Suppl 1**: S15-18.

UNIVERSITAS GADJAH MADA
ANALISIS FARMAKOEKONOMI AROMATASE INHIBITOR GENERASI KETIGA PADA TERAPI KANKER PAYUDARA ER+ HER2- PASCAMENOPAUSE
RIA ETIKASARI, Prof. Dr. apt. Tri Murti Andayani, Sp.FRS
Universitas Gadjah Mada, 2022 | Diunduh dari http://etd.repository.ugm.ac.id/

Kelly, C.M. dan Buzdar, A.U., 2010. Anastrozole. *Expert Opinion on Drug Safety*, **9**: 995–1003.

Kementerian Kesehatan, 2013. *Pedoman Penerapan Kajian Farmakoekonomi*. Kementerian Kesehatan Republik Indonesia.

Kementerian Kesehatan, 2015. *Pedoman Penyusunan Dan Penerapan Formularium Nasional*. Kementerian Kesehatan Republik Indonesia.

Kementerian Kesehatan, 2016. *Panduan Penatalaksanaan Kanker Payudara*. Kementerian Kesehatan Republik Indonesia.

Kementrian Kesehatan, 2017. *Buku Panduan Penilaian Teknologi Kesehatan : Efektifitas Klinis Dan Evaluasi Ekonomi*. Jakarta, Komite Penilaian Teknologi Kesehatan, Kementerian Kesehatan Republik Indonesia.

Kemeterian Kesehatan, 2015. *Stop Kanker*. Infodatin, Kementerian Kesehatan Republik Indonesia.

Khatiwoda, S.R., Dhungana, R.R., Sapkota, V.P., dan Singh, S., 2019. Estimating the Direct Cost of Cancer in Nepal: A Cross-Sectional Study in a Tertiary Cancer Hospital. *Frontiers in public health*, **7**: 160.

Khosrow-Khavar, F., Filion, K.B., Bouganim, N., Suissa, S., dan Azoulay, L., 2020. Aromatase Inhibitors and the Risk of Cardiovascular Outcomes in Women With Breast Cancer: A Population-Based Cohort Study. *Circulation*, **141**: 549–559.

Kouwenberg, C.A.E., Mureau, M.A.M., Kranenburg, L.W., Rakhorst, H., de Leeuw, D., Klem, T.M.A.L., dkk., 2021. Cost-utility analysis of four common surgical treatment pathways for breast cancer. *European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology*, **47**: 1299–1308.

Lawrenti, H., 2016. Letrozole sebagai Terapi Lini Pertama Kanker Payudara Stadium Lokal Lanjut atau Metastatik Reseptor Hormon Positif. *Cermin Dunia Kedokteran*, **43**: 377–381.

Leppert, W., Zajaczkowska, R., Wordliczek, J., Dobrogowski, J., Woron, J., dan Krzakowski, M., 2016. Pathophysiology and clinical characteristics of pain in most common locations in cancer patients. *Journal of physiology and pharmacology : an official journal of the Polish Physiological Society*, **67**: 787–799.

Li, J., Chen, Z., Su, K., dan Zeng, J., 2015. Clinicopathological classification and traditional prognostic indicators of breast cancer. *International journal of clinical and experimental pathology*, **8**: 8500–8505.

UNIVERSITAS
GADJAH MADA
ANALISIS FARMAKOEKONOMI AROMATASE INHIBITOR GENERASI KETIGA PADA TERAPI KANKER PAYUDARA ER+ HER2- PASCAMENOPAUSE
RIA ETIKASARI, Prof. Dr. apt. Tri Murti Andayani, Sp.FRS
Universitas Gadjah Mada, 2022 | Diunduh dari http://etd.repository.ugm.ac.id/

Liang, X., Margolis, K.L., Hendryx, M., Reeves, K., Wassertheil-Smoller, S., Weitlauf, J., dkk., 2017. Effect of depression before breast cancer diagnosis on mortality among postmenopausal women. *Cancer*, **123**: 3107–3115.

Lintermans, A., Neven, P., dan Paridaens, R., 2011. Drug safety evaluation of exemestane. *Expert Opinion on Drug Safety*, **10**: 473–487.

Lipton, A., Demers, L.M., Harvey, H.A., Kambic, K.B., Grossberg, H., Brady, C., dkk., 1995. Letrozole (CGS 20267). A phase I study of a new potent oral aromatase inhibitor of breast cancer. *Cancer*, **75**: 2132–2138.

Llombart-Cussac, A., Ruiz, A., Antón, A., Barnadas, A., Antolín, S., Alés-Martínez, J.E., dkk., 2012. Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer: final results from the Spanish Breast Cancer Group 2001-03 phase 2 randomized trial. *Cancer*, **118**: 241–247.

Lønning, P.E., 2004. Aromatase inhibitors in breast cancer. *Endocrine-related cancer*, **11**: 179–189.

Lønning, P.E., Paridaens, R., Thürlimann, B., Piscitelli, G., dan di Salle, E., 1997. Exemestane experience in breast cancer treatment. *The Journal of steroid biochemistry and molecular biology*, **61**: 151–155.

Mahajan, Anu, Rawal, Shruti, Bedi, PMS, Mahajan, Nipun, dan Sharma, Ajay, 2010. Aromatase Inhibitors : A New Hope for Breast Cancer Patients. *International Journal of Pharmaceutical Sciences and Research*, **1**: 27–40.

Malvia, S., Bagadi, S.A., Dubey, U.S., dan Saxena, S., 2017. Epidemiology of breast cancer in Indian women. *Asia-Pacific Journal of Clinical Oncology*, **13**: 289–295.

Marchetti, M., Caruggi, M., dan Colombo, G., 2004. Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian national health service. *Clinical Therapeutics*, **26**: 1546–1561.

Maurya, P.K., Murali, S., Jayaseelan, V., Thulasingam, M., dan Pandjatcharam, J., 2021. Economic Burden of Cancer Treatment in a Region in South India: A Cross Sectional Analytical Study. *Asian Pacific journal of cancer prevention : APJCP*, **22**: 3755–3762.

McClain, K.M., McCullough, L.E., Bradshaw, P.T., Shantakumar, S., Terry, M.B., Neugut, A.I., dkk., 2017. Age-Specific Indicators of a Healthy Lifestyle and Postmenopausal Breast Cancer. *Journal of women's health (2002)*, **26**: 1176–1184.

UNIVERSITAS
GADJAH MADA
ANALISIS FARMAKOEKONOMI AROMATASE INHIBITOR GENERASI KETIGA PADA TERAPI KANKER PAYUDARA ER+ HER2- PASCAMENOPAUSE
RIA ETIKASARI, Prof. Dr. apt. Tri Murti Andayani, Sp.FRS
Universitas Gadjah Mada, 2022 | Diunduh dari http://etd.repository.ugm.ac.id/

McDonald, E.S., Clark, A.S., Tchou, J., Zhang, P., dan Freedman, G.M., 2016. Clinical Diagnosis and Management of Breast Cancer. *Journal of nuclear medicine : official publication, Society of Nuclear Medicine*, **57 Suppl 1**: 9S-16S.

McPherson, K., Steel, C.M., dan Dixon, J.M., 2000. Breast cancer—epidemiology, risk factors, and genetics. *BMJ : British Medical Journal*, **321**: 624–628.

Meade, E. dan Dowling, M., 2012. Early breast cancer: diagnosis, treatment and survivorship. *British journal of nursing (Mark Allen Publishing)*, **21**: S4-8, S10.

Mehnert, A., 2011. Employment and work-related issues in cancer survivors. *Critical reviews in oncology/hematology*, **77**: 109–130.

Miller, W.R., 1989. Aromatase inhibitors in the treatment of advanced breast cancer. *Cancer treatment reviews*, **16**: 83–93.

Ministry of Health Malaysia, 2012. *Pharmacoeconomic Guideline for Malaysia*. Pharmaceutical Service Division, Ministry of Health Malaysia.

Momenimovahed, Z. dan Salehiniya, H., 2019. Epidemiological characteristics of and risk factors for breast cancer in the world. *Breast cancer (Dove Medical Press)*, **11**: 151–164.

Nadji, M., Gomez-Fernandez, C., Ganjei-Azar, P., dan Morales, A.R., 2005. Immunohistochemistry of Estrogen and Progesterone Receptors ReconsideredExperience With 5,993 Breast Cancers. *American Journal of Clinical Pathology*, **123**: 21–27.

Nahm, N., Mee, S., dan Marx, G., 2018. Efficacy of management strategies for aromatase inhibitor-induced arthralgia in breast cancer patients: a systematic review. *Asia-Pacific Journal of Clinical Oncology*, **0**: .

Ng, C.G., Mohamed, S., Kaur, K., Sulaiman, A.H., Zainal, N.Z., Taib, N.A., dkk., 2017. Perceived distress and its association with depression and anxiety in breast cancer patients. *PloS one*, **12**: e0172975–e0172975.

Ng, C.G., Mohamed, S., See, M.H., Harun, F., Dahlui, M., Sulaiman, A.H., dkk., 2015. Anxiety, depression, perceived social support and quality of life in Malaysian breast cancer patients: a 1-year prospective study. *Health and quality of life outcomes*, **13**: 205–205.

Njar, V.C. dan Brodie, A.M., 1999. Comprehensive pharmacology and clinical efficacy of aromatase inhibitors. *Drugs*, **58**: 233–255.

Noguchi, S., Ellis, M.J., Robertson, J.F.R., Thirlwell, J., Fazal, M., dan Shao, Z., 2018. Progression-free survival results in postmenopausal Asian women: subgroup analysis from a phase III randomized trial of fulvestrant 500 mg vs

UNIVERSITAS GADJAH MADA
ANALISIS FARMAKOEKONOMI AROMATASE INHIBITOR GENERASI KETIGA PADA TERAPI KANKER PAYUDARA ER+ HER2- PASCAMENOPAUSE
RIA ETIKASARI, Prof. Dr. apt. Tri Murti Andayani, Sp.FRS
Universitas Gadjah Mada, 2022 | Diunduh dari http://etd.repository.ugm.ac.id/

anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON). *Breast Cancer*, **25**: 356–364.

Nounou, M.I., ElAmrawy, F., Ahmed, N., Abdelraouf, K., Goda, S., dan Syed-Sha-Qhattal, H., 2015a. Breast Cancer: Conventional Diagnosis and Treatment Modalities and Recent Patents and Technologies. *Breast cancer : basic and clinical research*, **9**: 17–34. .

Ohno, S., Chen, Y., Sakamaki, H., Matsumaru, N., dan Tsukamoto, K., 2020. Factors associated with humanistic burden and indirect cost among patients with cancer in Japan. *Journal of medical economics*, **23**: 1570–1578.

Oktastika, H.R., Supadmi, W., dan Yuniarti, E., 2021. Analisis Cost Consequences Obat Kemoterapi pada Pasien Kanker Payudara di RS Pemerintah Kota Yogtakarta. *Majalah Farmaseutik*, **17**: 287–292.

Panigoro, S., Hernowo, B.S., Purwanto, H., Handojo, Haryono, S.J., Arif, W., dkk., 2015. Panduan Penatalaksanaan Kanker Payudara. Kementerian Kesehatan Republik Indonesia.

Parsekar, K., Howard Wilsher, S., Sweeting, A., Patel, A., dan Fordham, R., 2021. Societal costs of chemotherapy in the UK: an incidence-based cost-of-illness model for early breast cancer. *BMJ open*, **11**: e039412.

Plourde, P.V., Dyroff, M., dan Dukes, M., 1994. Arimidex: a potent and selective fourth-generation aromatase inhibitor. *Breast cancer research and treatment*, **30**: 103–111.

Pradelli, Lorenzo dan Wertheimer, Albert, 2012. *Pharmacoeconomics : Principles and Practice*, First. ed. SEEd, Torino Italy.

Pritchard, K.I., Burris, H.A. 3rd, Ito, Y., Rugo, H.S., Dakhil, S., Hortobagyi, G.N., dkk., 2013. Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2. *Clinical breast cancer*, **13**: 421-432.e8.

Pulido, C., Vendrell, I., Ferreira, A.R., Casimiro, S., Mansinho, A., Alho, I., dkk., 2017. Bone metastasis risk factors in breast cancer. *Ecancermedicalscience*, **11**: 715.

Purba, F.D., Hunfeld, J.A.M., Iskandarsyah, A., Fitriana, T.S., Sadarjoen, S.S., Passchier, J., dkk., 2018. Quality of life of the Indonesian general population: Test-retest reliability and population norms of the EQ-5D-5L and WHOQOL-BREF. *PloS one*, **13**: e0197098–e0197098.

Reich, M., Lesur, A., dan Perdrizet-Chevallier, C., 2008. Depression, quality of life and breast cancer: a review of the literature. *Breast cancer research and treatment*, **110**: 9–17.

UNIVERSITAS GADJAH MADA
ANALISIS FARMAKOEKONOMI AROMATASE INHIBITOR GENERASI KETIGA PADA TERAPI KANKER PAYUDARA ER+ HER2- PASCAMENOPAUSE
RIA ETIKASARI, Prof. Dr. apt. Tri Murti Andayani, Sp.FRS
Universitas Gadjah Mada, 2022 | Diunduh dari http://etd.repository.ugm.ac.id/

Reinert, T., Debiasi, M., Bines, J., dan Barrios, C.H., 2018. Trends in progression-free survival (PFS) and time to progression (TTP) over time within first-line aromatase inhibitors trials in hormone receptor-positive advanced breast cancer. *Breast Cancer Research and Treatment*, **168**: 457–465.

Robarge, J.D., Desta, Z., Nguyen, A.T., Li, L., Hertz, D., Rae, J.M., dkk., 2017. Effects of exemestane and letrozole therapy on plasma concentrations of estrogens in a randomized trial of postmenopausal women with breast cancer. *Breast cancer research and treatment*, **161**: 453–461.

Rustamadji, P. dan Marisca, S., 2018. Karakteristik Histopatologik dan Imunofenotipik Kanker Payudara di Rumah Sakit Cipto Mangunkusumo Jakarta, Indonesia. *Medicinus*, **6**: .

Sagara, Yasuaki, Kosha, S., Baba, S., Dokiya, F., Tamada, S., Sagara, Yoshiaki, dkk., 2010a. Adverse events and bone health during anastrozole therapy in postmenopausal Japanese breast cancer patients. *Breast cancer (Tokyo, Japan)*, **17**: 212–217.

Sakr, H., Hamed, R.H., Anter, A.H., dan Yossef, T., 2013. Sequential docetaxel as adjuvant chemotherapy for node-positive or/and T3 or T4 breast cancer: clinical outcome (Mansoura University). *Medical oncology (Northwood, London, England)*, **30**: 457.

Segel, Joel E, 2006. Cost-of-Illness Studies—A Primer. *RTI-UNC Center of Excellence in Health Promotion Economics, RTI International*, .

Sendur, M.A.N., Aksoy, S., Zengin, N., dan Altundag, K., 2013. Comparative efficacy study of 5-year letrozole or anastrozole in postmenopausal hormone receptor-positive early breast cancer. *Journal of B.U.ON. : official journal of the Balkan Union of Oncology*, **18**: 838–844.

Setiawan, D., Dusafitri, A., Galistiani, G.F., van Asselt, A.D.I., dan Postma, M.J., 2018. Health-Related Quality of Life of Patients with HPV-Related Cancers in Indonesia. *Value in health regional issues*, **15**: 63–69.

Setiawan, D., Suwantika, A., dan Endarti, D., 2017. *Farmakoekonomi Modeling*. UM Purwokerto Press.

Setyowibowo, H., Purba, F.D., Hunfeld, J.A.M., Iskandarsyah, A., Sadarjoen, S.S., Passchier, J., dkk., 2018. Quality of life and health status of Indonesian women with breast cancer symptoms before the definitive diagnosis: A comparison with Indonesian women in general. *PloS one*, **13**: e0200966–e0200966.

Simon, S.D., 2001. Understanding the odds ratio and the relative risk. *Journal of andrology*, **22**: 533–536.

UNIVERSITAS GADJAH MADA
ANALISIS FARMAKOEKONOMI AROMATASE INHIBITOR GENERASI KETIGA PADA TERAPI KANKER PAYUDARA ER+ HER2- PASCAMENOPAUSE
RIA ETIKASARI, Prof. Dr. apt. Tri Murti Andayani, Sp.FRS
Universitas Gadjah Mada, 2022 | Diunduh dari http://etd.repository.ugm.ac.id/

Smith, I., Yardley, D., Burris, H., De Boer, R., Amadori, D., McIntyre, K., dkk., 2017a. Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor–Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation (FACE) Trial. *Journal of Clinical Oncology*, **35**: 1041–1048.

Sommer, S. dan Fuqua, S.A.W., 2001. Estrogen receptor and breast cancer. *Seminars in Cancer Biology*, **11**: 339–352.

Soran, A., Soyder, A., Ozbas, S., Ozmen, V., Karanlik, H., Igci, A., dkk., 2020. The role of loco-regional treatment in long-term quality of life in de novo stage IV breast cancer patients: protocol MF07-01Q. *Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer*, .

Strasser-Weippl, K., Sudan, G., Ramjeesingh, R., Shepherd, L.E., O'Shaughnessy, J., Parulekar, W.R., dkk., 2018. Outcomes in women with invasive ductal or invasive lobular early stage breast cancer treated with anastrozole or exemestane in CCTG (NCIC CTG) MA.27. *European journal of cancer (Oxford, England : 1990)*, **90**: 19–25.

Su, M., Hua, X., Wang, J., Yao, N., Zhao, D., Liu, W., dkk., 2019. Health-related quality of life among cancer survivors in rural China. *Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation*, **28**: 695–702.

Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A., dkk., 2021. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA: a cancer journal for clinicians*, **71**: 209–249.

Suparman, Erna dan Suparman, Eddy, 2014b. Peran Estrogen dan Progesteron Terhadap Kanker Payudara. *JURNAL BIOMEDIK*, **6**: .

Tamirisa, N., Lin, H., Shen, Y., Shaitelman, S.F., Sri Karuturi, M., Giordano, S.H., dkk., 2020. Association of Chemotherapy With Survival in Elderly Patients With Multiple Comorbidities and Estrogen Receptor-Positive, Node-Positive Breast Cancer. *JAMA oncology*, **6**: 1548–1554.

Tarricone, R., 2006. Cost-of-illness analysis: What room in health economics? *Health Policy*, **77**: 51–63.

Tian, W., Wu, M., dan Deng, Y., 2018. Comparison of Changes in the Lipid Profiles of Eastern Chinese Postmenopausal Women With Early-Stage Breast Cancer Treated With Different Aromatase Inhibitors: A Retrospective Study. *Clinical pharmacology in drug development*, **7**: 837–843.

UNIVERSITAS
GADJAH MADA
ANALISIS FARMAKOEKONOMI AROMATASE INHIBITOR GENERASI KETIGA PADA TERAPI KANKER PAYUDARA ER+ HER2- PASCAMENOPAUSE
RIA ETIKASARI, Prof. Dr. apt. Tri Murti Andayani, Sp.FRS
Universitas Gadjah Mada, 2022 | Diunduh dari http://etd.repository.ugm.ac.id/

Trunet, P.F., Mueller, P., Bhatnagar, A.S., Dickes, I., Monnet, G., dan White, G., 1993. Open dose-finding study of a new potent and selective nonsteroidal aromatase inhibitor, CGS 20 267, in healthy male subjects. *The Journal of clinical endocrinology and metabolism*, **77**: 319–323.

van de Velde, C.J.H., Rea, D., Seynaeve, C., Putter, H., Hasenburg, A., Vannetzel, J.-M., dkk., 2011. Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. *Lancet (London, England)*, **377**: 321–331.

Verma, S. dan Rocchi, A., 2003. Economic evaluation of antiaromatase agents in the second-line treatment of metastatic breast cancer. *Supportive Care in Cancer*, **11**: 728–734.

Villar, R.R., Fernández, S.P., Garea, C.C., Pillado, M.T.S., Barreiro, V.B., dan Martín, C.G., 2017. Quality of life and anxiety in women with breast cancer before and after treatment. *Revista latino-americana de enfermagem*, **25**: e2958–e2958.

Wallwiener, M., Simoes, E., Sokolov, A.N., Brucker, S.Y., Fasching, P.A., dan Graf, J., 2016. Health-related Quality of Life in Metastatic and Adjuvant Breast Cancer Patients. *Geburtshilfe und Frauenheilkunde*, **76**: 1065–1073.

Wang, L., Zhang, S., dan Wang, X., 2020. The Metabolic Mechanisms of Breast Cancer Metastasis. *Frontiers in oncology*, **10**: 602416.

Wangsa, I., Wayan, N., Adiputra, P., dan Dewi, N., 2018. Gambaran stadium dan jenis histopatologi kanker payudara di Subbagian Bedah Onkologi RSUP Sanglah Denpasar tahun 2015-2016. *Intisari Sains Medis*, **9**: .

WHO, 2005. *Guidelines for Estimating the Economic Burden of Diarrhoeal Disease, with Focus on Assessing the Costs of Rotavirus Diarrhoea*. World Health Organization Department of Immunization, Vaccines and Biologicals.

Wiseman, L.R. dan Adkins, J.C., 1998. Anastrozole. A review of its use in the management of postmenopausal women with advanced breast cancer. *Drugs & aging*, **13**: 321–332.

Yang, Y., Pan, W., Tang, X., Wu, S., dan Sun, X., 2017. A meta-analysis of randomized controlled trials comparing the efficacy and safety of anastrozole versus tamoxifen for breast cancer. *Oncotarget*, **8**: 48362–48374.

Yosmar, R., Ningsih, L., dan Ifmaily, I., 2020. Studi Analisa Efektivitas Biaya pada Pasien Kanker Payudara yang Menjalani Kemoterapi di RSUP DR. M. Djamil Padang. *Jurnal Farmasi Higea*, **12**: 19–31.

Yu, Z., Guo, X., Jiang, Y., Teng, L., Luo, J., Wang, P., dkk., 2018. Adjuvant endocrine monotherapy for postmenopausal early breast cancer patients with

UNIVERSITAS
GADJAH MADA
ANALISIS FARMAKOEKONOMI AROMATASE INHIBITOR GENERASI KETIGA PADA TERAPI KANKER PAYUDARA ER+ HER2- PASCAMENOPAUSE
RIA ETIKASARI, Prof. Dr. apt. Tri Murti Andayani, Sp.FRS
Universitas Gadjah Mada, 2022 | Diunduh dari http://etd.repository.ugm.ac.id/

hormone-receptor positive: a systemic review and network meta-analysis. *Breast Cancer*, **25**: 8–16.

Zdenkowski, N., Tesson, S., Lombard, J., Lovell, M., Hayes, S., Francis, P.A., dkk., 2016. Supportive care of women with breast cancer: key concerns and practical solutions. *The Medical journal of Australia*, **205**: 471–475.

Zhang, J., Huang, Y., Wang, C., He, Y., Zheng, S., dan Wu, K., 2017b. Efficacy and safety of endocrine monotherapy as first-line treatment for hormone-sensitive advanced breast cancer: A network meta-analysis. *Medicine*, **96**: e7846.

Zilembo, N., Noberasco, C., Bajetta, E., Martinetti, A., Mariani, L., Orefice, S., dkk., 1995. Endocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitor. *British journal of cancer*, **72**: 1007–1012.